Abstract: The invention relates to a method for the preparation of trans- or cis-diammoniumdichlorodihydroxoplatinum(IV) and derivatives thereof. What is suggested is reacting trans- or cis-diammoniumdichloroplatinum(II) with a solution comprising >30% peroxide at temperatures below 30° C. and dissolving the product thus obtained in a mineral acid and subsequently precipitating with an alkaline solution.

Abstract: The present invention relates to water soluble esters of [N-(4-amino-2-butynyl)] or 4-(N-substituted amino)-2-butynyl-1-esters and methods for production of said esters and the use of the esters for treatment of cancer.

Abstract: The invention relates to combined agents comprising cis-hydroxyproline (CHP) and gemcitabine and to the use of said agents in tumor prophylaxis and therapy.

Abstract: The invention relates to the use of cis-hydroxy proline for the inhibition of glutathione s-transferases and/or collagen IV, in addition to a method which is used to lower the concentration of glutathione s-transferase and/or collagen IV in vitro or in vivo, in addition to anti-collagen IV/collagen IV-lowerers or glutathione s-transferase agents/glutathione s-transferase-lowerers.

Abstract: The invention relates to a pharmaceutical agent, particularly a chemotherapeutical agent, comprising cis-diammoniumdichloro-trans-dihydroxoplatinum(IV) or salts and/or derivatives thereof in the form of capsules, tablets, creams, ointments and infusion solutions, and to the production of said pharmaceutical agent; the invention also relates to the use of such pharmaceutical agents in the treatment of tumor diseases.

Abstract: The invention relates to a composition of proteins, peptides and/or peptide components, to a pharmaceutical agent comprising said composition, to a method for the production of said composition, and to the use thereof in the prophylaxis or therapy of persons, animals and/or patients with pathogenic modifications and/or cellular immunodeficiencies, especially cancer, septicemia or allergic reactions, in connection with a cytostatic agent therapy, chemotherapy and/or radiotherapy and/or as a prophylaxis and/or therapy in connection with fatigue syndrome and/or accidents with nuclear, biological, chemical and/or radioactive substances and/or materials.

Abstract: The present invention relates to a pharmaceutical composition comprising of proline or proline derivatives or their salts, esters, isomers, racemates, enantiomeres or prodrugs together with an anti-cancer ligand, preferably an antibody directed to a tumour antigen. The invention is also directed to the use of proline or proline derivatives or their salts, esters, isomers or prodrugs for the manufacture of a pharmaceutical composition for treating cancer and to a method of cancer treatment by administering said composition.